Hashemi Marjan M, Holden Brett S, Coburn Jordan, Taylor Maddison F, Weber Scott, Hilton Brian, Zaugg Aaron L, McEwan Colten, Carson Richard, Andersen Joshua L, Price John C, Deng Shenglou, Savage Paul B
Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, United States.
Front Microbiol. 2019 Feb 18;10:210. doi: 10.3389/fmicb.2019.00210. eCollection 2019.
Use of chlorhexidine in clinical settings has led to concerns that repeated exposure of bacteria to sub-lethal doses of chlorhexidine might result in chlorhexidine resistance and cross resistance with other cationic antimicrobials including colistin, endogenous antimicrobial peptides (AMPs) and their mimics, ceragenins. We have previously shown that colistin-resistant Gram-negative bacteria remain susceptible to AMPs and ceragenins. Here, we investigated the potential for cross resistance between chlorhexidine, colistin, AMPs and ceragenins by serial exposure of standard strains of Gram-negative bacteria to chlorhexidine to generate resistant populations of organisms. Furthermore, we performed a proteomics study on the chlorhexidine-resistant strains and compared them to the wild-type strains to find the pathways by which bacteria develop resistance to chlorhexidine. Serial exposure of Gram-negative bacteria to chlorhexidine resulted in four- to eight-fold increases in minimum inhibitory concentrations (MICs). Chlorhexidine-resistant organisms showed decreased susceptibility to colistin (8- to 32-fold increases in MICs) despite not being exposed to colistin. In contrast, chlorhexidine-resistant organisms had the same MICs as the original strains when tested with representative AMPs (LL-37 and magainin I) and ceragenins (CSA-44 and CSA-131). These results imply that there may be a connection between the emergence of highly colistin-resistant Gram-negative pathogens and the prevalence of chlorhexidine usage. Yet, use of chlorhexidine may not impact innate immune defenses (e.g., AMPs) and their mimics (e.g., ceragenins). Here, we also show that chlorhexidine resistance is associated with upregulation of proteins involved in the assembly of LPS for outer membrane biogenesis and virulence factors in . Additionally, resistance to chlorhexidine resulted in elevated expression levels of proteins associated with chaperones, efflux pumps, flagella and cell metabolism. This study provides a comprehensive overview of the evolutionary proteomic changes in following exposure to chlorhexidine and colistin. These results have important clinical implications considering the continuous application of chlorhexidine in hospitals that could influence the emergence of colistin-resistant strains.
在临床环境中使用洗必泰引发了人们的担忧,即细菌反复接触亚致死剂量的洗必泰可能会导致对洗必泰产生耐药性,并与其他阳离子抗菌剂产生交叉耐药性,这些抗菌剂包括多粘菌素、内源性抗菌肽(AMPs)及其模拟物、杀菌素。我们之前已经表明,耐多粘菌素的革兰氏阴性菌对AMPs和杀菌素仍然敏感。在此,我们通过将革兰氏阴性菌的标准菌株连续暴露于洗必泰以产生耐药菌群体,研究了洗必泰、多粘菌素、AMPs和杀菌素之间交叉耐药的可能性。此外,我们对耐洗必泰菌株进行了蛋白质组学研究,并将它们与野生型菌株进行比较,以找出细菌对洗必泰产生耐药性的途径。革兰氏阴性菌连续暴露于洗必泰导致最低抑菌浓度(MICs)增加了4至8倍。耐洗必泰的生物体对多粘菌素的敏感性降低(MICs增加了8至32倍),尽管它们没有接触过多粘菌素。相比之下,当用代表性的AMPs(LL - 37和蛙皮素I)和杀菌素(CSA - 44和CSA - 131)进行测试时,耐洗必泰的生物体与原始菌株具有相同的MICs。这些结果表明,高度耐多粘菌素的革兰氏阴性病原体的出现与洗必泰的广泛使用之间可能存在联系。然而,洗必泰的使用可能不会影响先天免疫防御(如AMPs)及其模拟物(如杀菌素)。在此,我们还表明,洗必泰耐药性与参与外膜生物合成的脂多糖组装和毒力因子的蛋白质上调有关。此外,对洗必泰的耐药性导致与伴侣蛋白、外排泵、鞭毛和细胞代谢相关的蛋白质表达水平升高。这项研究全面概述了暴露于洗必泰和多粘菌素后细菌的进化蛋白质组学变化。考虑到洗必泰在医院中的持续应用可能会影响耐多粘菌素菌株的出现,这些结果具有重要的临床意义。